Kristina M. McCammon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kristina M. McCammon has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Bradley Charles Bundy
Department of Chemical and Biological Engineering, Brigham Young University, Provo, UT 84602, USA
2 shared publications - Dennis Della Corte
Department of Physics and Astronomy, Brigham Young University, Provo, UT 84602, USA
2 shared publications - William P. Heaps
Department of Physics and Astronomy, Brigham Young University, Provo, UT 84602, USA
2 shared publications - Anne Elise Packard
Department of Physics and Astronomy, Brigham Young University, Provo, UT 84602, USA
1 shared publication - Corbyn Kubalek
Department of Physics and Astronomy, Brigham Young University, Provo, UT 84602, USA
1 shared publication - Joseph P. Talley
Department of Chemical and Biological Engineering, Brigham Young University, Provo, UT 84602, USA
1 shared publication
Latest Publications
- Open Access
- 5 July 2026
- Published by MDPI AG in Chemengineering
- Vol. 10 (7) , 85
Biological Functions of Glycosylation and Their Application in Glycoengineered Therapeutics
Glycosylation is the most common post-translational modification in the human proteome, with over half of all human proteins bearing covalently attached glycans. These glycan structures direct protein folding through ER quality control machinery, shield polypeptides from proteolytic degradation, regulate circulatory half-life via the asialoglycoprotein receptor, and serve as molecular signals for immune recognition and intracellular trafficking. For biopharmaceuticals, which constitute a rapidly growing share of approved drugs, glycan profiles are critical quality attributes that directly determine clinical efficacy and safety. Yet achieving the correct glycosylation on a therapeutic protein remains one of the field’s central challenges, as glycan biosynthesis is non-template-driven and highly sensitive to expression system and manufacturing conditions. This review connects the biological functions of glycosylation to the practical strategies of glycoengineering, examining how sequence design, expression system selection, and downstream enzymatic remodeling are used to optimize therapeutic glycoproteins. Clinical case studies spanning monoclonal antibodies, cytokines, and enzyme replacement therapies illustrate how glycan engineering translates into improved patient outcomes. We conclude by surveying emerging technologies poised to make precisely glycosylated therapeutics more accessible.
- 5 July 2026
- Published by MDPI AG in Chemengineering
- Vol. 10 (7) , 85
Open AccessBiological Functions of Glycosylation and Their Application in Glycoengineered Therapeutics
Glycosylation is the most common post-translational modification in the human proteome, with over half of all human proteins bearing covalently attached glycans. These glycan structures direct protein folding through ER quality control machinery, shield polypeptides from proteolytic degradation, regulate circulatory half-life via the asialoglycoprotein receptor, and serve as molecular signals for immune recognition and intracellular trafficking. For biopharmaceuticals, which constitute a rapidly growing share of approved drugs, glycan profiles are critical quality attributes that directly determine clinical efficacy and safety. Yet achieving the correct glycosylation on a therapeutic protein remains one of the field’s central challenges, as glycan biosynthesis is non-template-driven and highly sensitive to expression system and manufacturing conditions. This review connects the biological functions of glycosylation to the practical strategies of glycoengineering, examining how sequence design, expression system selection, and downstream enzymatic remodeling are used to optimize therapeutic glycoproteins. Clinical case studies spanning monoclonal antibodies, cytokines, and enzyme replacement therapies illustrate how glycan engineering translates into improved patient outcomes. We conclude by surveying emerging technologies poised to make precisely glycosylated therapeutics more accessible.
- Top Cited PapersOpen Access
- 13 January 2026
- Published by MDPI AG in Biophysica
- Vol. 6 (1) , 4
Molecular Survival Strategies Against Kidney Filtration: Implications for Therapeutic Protein Engineering
The glomerular filtration barrier poses a significant challenge for circulating proteins, with molecules below ~60–70 kDa facing rapid renal clearance. Endogenous proteins have evolved sophisticated evasion mechanisms including oligomerization, carrier binding, electrostatic repulsion, and FcRn-mediated recycling. Understanding these natural strategies provides blueprints for engineering therapeutic proteins with improved pharmacokinetics. This review examines how endogenous proteins resist filtration, evaluates their application in protein engineering, and discusses clinical translation including established technologies (PEGylation, Fc-fusion) and emerging strategies (albumin-binding domains, glycoengineering). We address critical challenges of balancing half-life extension with tissue penetration, biological activity, and immunogenicity—essential considerations for the rational design of next-generation therapeutics with optimized dosing and enhanced efficacy.
- 13 January 2026
- Published by MDPI AG in Biophysica
- Vol. 6 (1) , 4
Top Cited PapersOpen AccessMolecular Survival Strategies Against Kidney Filtration: Implications for Therapeutic Protein Engineering
The glomerular filtration barrier poses a significant challenge for circulating proteins, with molecules below ~60–70 kDa facing rapid renal clearance. Endogenous proteins have evolved sophisticated evasion mechanisms including oligomerization, carrier binding, electrostatic repulsion, and FcRn-mediated recycling. Understanding these natural strategies provides blueprints for engineering therapeutic proteins with improved pharmacokinetics. This review examines how endogenous proteins resist filtration, evaluates their application in protein engineering, and discusses clinical translation including established technologies (PEGylation, Fc-fusion) and emerging strategies (albumin-binding domains, glycoengineering). We address critical challenges of balancing half-life extension with tissue penetration, biological activity, and immunogenicity—essential considerations for the rational design of next-generation therapeutics with optimized dosing and enhanced efficacy.